Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest Up 11.8% in December
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest Up 11.8% in December
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) was the recipient of a significant increase in short interest in December. As of December 30th, there was short interest totalling 4,740,000 shares, an increase of 11.8% from the December 15th total of 4,240,000 shares. Based on an average daily volume of 951,300 shares, the short-interest ratio is presently 5.0 days. Currently, 4.6% of the shares of the stock are short sold.
箭頭製藥公司(納斯達克:ARWR-GET評級)是12月份空頭股數大幅增長的接受者。截至12月30日,空頭股數共有474萬股,比12月15日的424萬股增加了11.8%。以日均成交量951,300股計算,目前短息比率為5.0天。目前,該股有4.6%的股份被賣空。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Several research firms recently weighed in on ARWR. StockNews.com began coverage on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 12th. They set a "hold" rating for the company. HC Wainwright cut their target price on shares of Arrowhead Pharmaceuticals from $110.00 to $90.00 and set a "buy" rating for the company in a research note on Tuesday, December 6th. Chardan Capital cut their target price on shares of Arrowhead Pharmaceuticals from $82.00 to $60.00 in a research note on Tuesday, January 10th. SVB Leerink dropped their price objective on shares of Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a "market perform" rating for the company in a research note on Tuesday, November 29th. Finally, B. Riley dropped their price objective on shares of Arrowhead Pharmaceuticals from $65.00 to $59.00 and set a "buy" rating for the company in a research note on Wednesday, November 30th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $59.22.
幾家研究公司最近也加入了ARWR的行列。股票新聞網站在10月12日星期三的一份研究報告中開始對箭頭製藥公司的股票進行報道。他們為該公司設定了“持有”評級。12月6日,HC Wainwright在一份研究報告中將箭頭製藥公司的股票目標價從110.00美元下調至90美元,並在一份研究報告中設定了該公司的“買入”評級。Chardan Capital在1月10日星期二的一份研究報告中將箭頭製藥公司的股票目標價從82.00美元下調至60.00美元。11月29日,SVB Leerink在一份週二的研究報告中將箭頭製藥公司的股票目標價從33.00美元下調至31.00美元,併為該公司設定了“市場表現”評級。最後,B.萊利在11月30日星期三的一份研究報告中將箭頭製藥公司的股票目標價從65.00美元下調至59.00美元,併為該公司設定了“買入”評級。三位分析師對該股的評級為持有,七位分析師對該股的評級為買入。根據MarketBeat.com的數據,箭頭製藥目前的平均評級為“中等買入”,共識目標價為59.22美元。
Insider Transactions at Arrowhead Pharmaceuticals
箭頭製藥公司的內幕交易
In other news, Director William D. Waddill sold 3,200 shares of the stock in a transaction on Monday, January 9th. The shares were sold at an average price of $30.00, for a total value of $96,000.00. Following the completion of the sale, the director now directly owns 28,950 shares of the company's stock, valued at $868,500. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Patrick O'brien sold 17,500 shares of the firm's stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $38.33, for a total transaction of $670,775.00. Following the completion of the transaction, the chief operating officer now directly owns 363,375 shares of the company's stock, valued at $13,928,163.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William D. Waddill sold 3,200 shares of the firm's stock in a transaction on Monday, January 9th. The shares were sold at an average price of $30.00, for a total transaction of $96,000.00. Following the transaction, the director now directly owns 28,950 shares of the company's stock, valued at $868,500. The disclosure for this sale can be found here. Insiders sold a total of 109,966 shares of company stock valued at $4,050,435 over the last three months. Corporate insiders own 3.20% of the company's stock.
另一則消息是,董事威廉·D·沃迪爾在1月9日週一的一次交易中出售了3,200股該公司股票。這些股票的平均價格為30.00美元,總價值為9.6萬美元。出售完成後,董事現在直接持有該公司28,950股股票,價值868,500美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站。在相關新聞中,首席運營官帕特里克·奧布萊恩在1月3日星期二的一次交易中出售了17,500股該公司的股票。這些股票的平均價格為38.33美元,總成交額為670,775.00美元。交易完成後,首席運營官現在直接擁有363,375股公司股票,價值13,928,163.75美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。此外,威廉·D·沃迪爾在1月9日星期一的一次交易中出售了3,200股董事股票。這些股票的平均價格為30.00美元,總成交額為9.6萬美元。交易完成後,董事現在直接持有該公司28,950股股票,價值868,500美元。關於這次銷售的披露可以找到這裏。過去三個月,內部人士總共出售了109,966股公司股票,價值4,050,435美元。公司內部人士持有該公司3.20%的股份。
Institutional Investors Weigh In On Arrowhead Pharmaceuticals
機構投資者看好箭頭製藥公司
Arrowhead Pharmaceuticals Trading Down 3.1 %
箭頭製藥公司股價下跌3.1%
Arrowhead Pharmaceuticals stock opened at $32.70 on Tuesday. The firm has a 50-day moving average price of $33.89 and a 200-day moving average price of $36.57. The firm has a market capitalization of $3.47 billion, a PE ratio of -19.46 and a beta of 1.26. Arrowhead Pharmaceuticals has a 12-month low of $26.81 and a 12-month high of $56.25.
週二,箭頭製藥的股票開盤報32.70美元。該公司的50日移動均線價格為33.89美元,200日移動均線價格為36.57美元。該公司市值為34.7億美元,市盈率為-19.46,貝塔係數為1.26。箭頭製藥的12個月低點為26.81美元,12個月高位為56.25美元。
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last released its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.24). The firm had revenue of $31.58 million during the quarter, compared to the consensus estimate of $107.60 million. Arrowhead Pharmaceuticals had a negative return on equity of 40.23% and a negative net margin of 71.01%. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals will post -0.86 earnings per share for the current fiscal year.
箭頭製藥(納斯達克:ARWR-GET評級)最近一次發佈財報是在11月28日(星期一)。這家生物技術公司公佈了該季度每股收益(EPS)(0.81美元),低於(0.57美元)和(0.24美元)的普遍預期。該公司本季度營收為3158萬美元,而市場普遍預期為1.076億美元。箭頭製藥的淨資產收益率為負40.23%,淨利潤率為負71.01%。賣方分析師預測,作為一個整體,箭頭製藥公司本財年的每股收益將達到0.86美元。
About Arrowhead Pharmaceuticals
關於箭頭製藥公司
(Get Rating)
(獲取評級)
Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.
箭頭製藥公司是一家生物製藥公司,致力於開發通過沉默導致頑固性疾病的基因來治療頑固性疾病的藥物。這些公司的臨牀前候選藥物包括ARO-ANG3、ARO-AAT、ARO-APOC3、ARO-HIF2、ARO-HSD、ARO-LUNG2、ARO-COV和ARO-ENaC。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
- Energy Surge: Four Oil-And-Gas Stocks Setting Up In Bullish Bases
- 免費獲取StockNews.com關於箭頭製藥的研究報告(ARWR)
- Under Armor Stock的新任CEO是最糟糕的嗎?
- 分析師喜歡斯凱奇美國公司的Fit
- 微軟投資ChatGBT對微軟股票意味着什麼?
- 我們能相信標普500指數的漲勢嗎
- 能源飆升:四隻石油和天然氣類股看漲
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《箭頭藥業日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對箭頭製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。